

# NAP1L4 Rabbit pAb

NAP1L4 Rabbit pAb

Catalog # AP57353

## Product Information

---

<b>Application</b>	IHC-P, IHC-F, IF
<b>Primary Accession</b>	<a href="#">Q99733</a>
<b>Reactivity</b>	Human
<b>Predicted</b>	Mouse, Rat, Dog, Pig, Horse, Sheep
<b>Host</b>	Rabbit
<b>Clonality</b>	Polyclonal
<b>Calculated MW</b>	42823
<b>Physical State</b>	Liquid
<b>Immunogen</b>	KLH conjugated synthetic peptide derived from human NAP1L4
<b>Epitope Specificity</b>	2-100/375
<b>Isotype</b>	IgG
<b>Purity</b>	affinity purified by Protein A
<b>Buffer</b>	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
<b>SUBCELLULAR LOCATION</b>	Ubiquitous. Biallelically expressed in fetal and adult tissues. Highest levels in testis.
<b>SIMILARITY</b>	Belongs to the nucleosome assembly protein (NAP) family.
<b>Post-translational modifications</b>	Polyglutamylated by TTL4, a modification that occurs exclusively on glutamate residues and results in polyglutamate chains on the gamma-carboxyl group. Some residues may also be monoglycylated but not polyglycylated due to the absence of functional TTL10 in human.
<b>Important Note</b>	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
<b>Background Descriptions</b>	This gene encodes a member of the nucleosome assembly protein (NAP) family which can interact with both core and linker histones. It can shuttle between the cytoplasm and nucleus, suggesting a role as a histone chaperone. This gene is one of several located near the imprinted gene domain of 11p15.5, an important tumor-suppressor gene region. Alterations in this region have been associated with the Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast cancer. [provided by RefSeq, Jul 2008]

## Additional Information

---

<b>Gene ID</b>	4676
<b>Other Names</b>	Nucleosome assembly protein 1-like 4, Nucleosome assembly protein 2, NAP-2, NAP1L4 ( <a href="#">HGNC:7640</a> )
<b>Dilution</b>	IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
<b>Storage</b>	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When

reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

## Protein Information

---

<b>Name</b>	NAP1L4 ( <a href="#">HGNC:7640</a> )
<b>Function</b>	Acts as a histone chaperone in nucleosome assembly.
<b>Cellular Location</b>	Nucleus. Cytoplasm. Note=Present in the cytoplasm and excluded from the nucleus during G0/G1 phase, then relocates to the nucleus by the time cells are in S phase (PubMed:9325046). Phosphorylated form localizes in the cytoplasm during the G0/G1 transition, whereas dephosphorylation leads to relocalization into the nucleus at the G1/S- boundary (PubMed:10764593).
<b>Tissue Location</b>	Ubiquitous. Biallelically expressed in fetal and adult tissues. Highest levels in testis.


## Background

---

This gene encodes a member of the nucleosome assembly protein (NAP) family which can interact with both core and linker histones. It can shuttle between the cytoplasm and nucleus, suggesting a role as a histone chaperone. This gene is one of several located near the imprinted gene domain of 11p15.5, an important tumor-suppressor gene region. Alterations in this region have been associated with the Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast cancer. [provided by RefSeq, Jul 2008]

## Images

---



Paraformaldehyde-fixed, paraffin embedded (Human brain glioma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (NAP1L4) Polyclonal Antibody, Unconjugated (AP57353) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructions and DAB staining.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.